Capan 2

Cell culture materials were obtained from Gibco; Thermo Fisher Scientific, Inc. (Waltham, MA, USA), unless otherwise indicated. The Panc1, MIAPaCa-2 and Capan-2 cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and were used within 4 months of receipt. Panc1 and MIAPaCa-2 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 µg/ml streptomycin and 2 mM glutamine (PSG). Capan-2 cells were grown in McCoys 5A media (ATCC) supplemented with 10% FBS and PSG. The H6c7 human pancreatic duct epithelial cell line was obtained from Kerafast, Inc. (Boston, MA, USA) and was used within 4 months of purchase. H6c7 cells were grown in keratinocyte serum-free media containing EGF and bovine pituitary extract (cat. no. 17005042; Gibco; Thermo Fisher Scientific, Inc.). Cells were routinely maintained at 37°C in a humidified atmosphere containing 5% CO, and were split 2-3 times weekly to maintain sub-confluent cultures. Cultures were routinely tested for mycoplasma contamination using the MycoFluor™ Mycoplasma Detection kit (Invitrogen; Thermo Fisher Scientific, Inc.).

We used 16 pancreatic cancer cell lines (PK1, PK9, PK45P, PK45H, PK59, KLM1, SUIT‐2, SNU‐324, SNU‐410, PANC1, MiaPaCa‐2, Capan‐2, Hs766T, KP‐1N, PSN‐1, and AsPC‐1). PK1, PK9, PK45P, PK45H, PK59, KLM1, SUIT‐2, and MCF7 human breast cancer cells were obtained from the Cell Resource Center for the Biomedical Research Institute of Development, Aging and Cancer, Tohoku University (Miyagi, Japan). SNU‐324 and SNU‐410 were obtained from the Korean Cell Line Bank (Seoul, Korea). PANC1, MiaPaCa‐2, and Capan‐2 were obtained from American Type Culture Collection (ATCC) (Manassas, VA, USA). AsPC‐1 was obtained from DS Pharma Biomedical (Osaka, Japan). COBL human lymphoid cells were previously established in our laboratory.7 Capan‐2 cells (HTB‐80; ATCC) were grown in McCoy's 5A modified medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS at 37°C. SUIT‐2 cells were grown in minimum essential medium (Invitrogen) with 10% FBS at 37°C.17 MiaPaCa‐2 cells were grown in minimum essential medium supplemented with 10% FBS and non‐essential amino acids.18 Hs766T and PANC1 cells were grown in DMEM supplemented with 10% FBS at 37°C.19, 20 KP‐1N, PSN‐1, AsPC‐1, PK59, PK9, KLM1, PK1, PK45H, PK45P, SNU‐324, SNU‐410, and COBL cells were maintained in RPMI‐1640 medium (Invitrogen) supplemented with 10% FBS at 37°C.7, 21, 22, 23, 24, 25, 26, 27

Human ovarian adenocarcinoma OVCAR3 and SKOV3 cells were purchased from American Type Culture Collection (ATCC) in 2013. Both cell lines were used for implanting tumors in mice between passages 3 and 6 after the first thaw of the source vial. Human pancreatic ductal adenocarcinoma (PDAC) cell lines Capan-2, BxPC-3, and MIAPaCa-2 were purchased from ATCC in 2014–2015 and used for implanting tumors in mice between passages 3 and 6 after the first thaw of the source vial. S2-028 and T3M-4 cell lines were provided by the laboratory of Dr. Hollingsworth at the University of Nebraska Medical Center (UNMC) and used between passages 40 and 50 for implanting tumors in mice. In addition to routine testing for mycoplasma using the Lonza MycoAlert mycoplasma detection kit (LT07-418), all cell lines were authenticated by STR profiling at MSKCC and UNMC repeatedly between 2009 and 2018. Ovarian cancer patient-derived xenograft (PDX) lines OvCa PDX0003, PDX0004, and PDX0012 were obtained via IRB approval and maintained by the antitumor assessment core at MSKCC, sequenced via Integrated Mutation Profiling for Actionable Cancer Targets (IMPACT), and used at passage 4 for the studies described herein.